noscript

News and Announcements

Cellmid Ltd – European Patent Allowed for Treating Vascular Occlusive Disease

  • Published January 21, 2013 1:58PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates
  • Patent for the use of anti-midkine agents to prevent and treat blood vessel obstruction allowed in Europe 
  • Further IP protection for Cellmid in cardiovascular diseases and in midkine inhibitors 
  • Composition of matter for siRNA molecules targeting midkine also covered 
SYDNEY, 21 January 2013: Cellmid Limited (ASX: CDY) advises that the European Patent Office (EPO) has issued a Rule 71(3) Communication indicating that it intends to grant Cellmid’s patent application 06746805.8 entitled “Pharmaceutical composition for vascular occlusive disease”. The application was filled in May 2006 and the patent is expected to expire in 2026.
To read a full ASX announcement, please download a document below.
Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now